Overcoming the Black Dog: Ketamine and esketamine for resistant depression
In 2000, John Krystal’s group at Yale discovered that a single sub-anaesthetic dose of intravenous ketamine provided several days of symptomatic relief in a small group of depressed patients. This effect has been widely confirmed and has led recently to the licensing of intranasal esketamine for the treatment of patients with refractory depressive illness. In this talk we will describe the development of ketamine as an antidepressant, discuss the possible mechanisms involved in its action, and appraise the likely utility of ketamine and esketamine for clinical use in the NHS.
Date: 4 February 2020, 9:30 (Tuesday, 3rd week, Hilary 2020)
Venue: Warneford Hospital, Headington OX3 7JX
Venue Details: Seminar Room, Department of Psychiatry
Speakers: Professor Phil Cowen (University of Oxford), Dr Rupert McShane (University of Oxford)
Organising department: Department of Psychiatry
Organiser: Elizabeth Thomas (University of Oxford)
Part of: Psychiatry Seminars
Booking required?: Not required
Audience: Members of the University only
Editor: Elizabeth Thomas